Cargando…

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis

BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We as...

Descripción completa

Detalles Bibliográficos
Autores principales: Strengert, Monika, Becker, Matthias, Ramos, Gema Morillas, Dulovic, Alex, Gruber, Jens, Juengling, Jennifer, Lürken, Karsten, Beigel, Andrea, Wrenger, Eike, Lonnemann, Gerhard, Cossmann, Anne, Stankov, Metodi V., Dopfer-Jablonka, Alexandra, Kaiser, Philipp D., Traenkle, Bjoern, Rothbauer, Ulrich, Krause, Gérard, Schneiderhan-Marra, Nicole, Behrens, Georg M.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357427/
https://www.ncbi.nlm.nih.gov/pubmed/34391096
http://dx.doi.org/10.1016/j.ebiom.2021.103524
_version_ 1783737128034762752
author Strengert, Monika
Becker, Matthias
Ramos, Gema Morillas
Dulovic, Alex
Gruber, Jens
Juengling, Jennifer
Lürken, Karsten
Beigel, Andrea
Wrenger, Eike
Lonnemann, Gerhard
Cossmann, Anne
Stankov, Metodi V.
Dopfer-Jablonka, Alexandra
Kaiser, Philipp D.
Traenkle, Bjoern
Rothbauer, Ulrich
Krause, Gérard
Schneiderhan-Marra, Nicole
Behrens, Georg M.N.
author_facet Strengert, Monika
Becker, Matthias
Ramos, Gema Morillas
Dulovic, Alex
Gruber, Jens
Juengling, Jennifer
Lürken, Karsten
Beigel, Andrea
Wrenger, Eike
Lonnemann, Gerhard
Cossmann, Anne
Stankov, Metodi V.
Dopfer-Jablonka, Alexandra
Kaiser, Philipp D.
Traenkle, Bjoern
Rothbauer, Ulrich
Krause, Gérard
Schneiderhan-Marra, Nicole
Behrens, Georg M.N.
author_sort Strengert, Monika
collection PubMed
description BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. FINDINGS: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. INTERPRETATION: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. FUNDING: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism.
format Online
Article
Text
id pubmed-8357427
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83574272021-08-12 Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis Strengert, Monika Becker, Matthias Ramos, Gema Morillas Dulovic, Alex Gruber, Jens Juengling, Jennifer Lürken, Karsten Beigel, Andrea Wrenger, Eike Lonnemann, Gerhard Cossmann, Anne Stankov, Metodi V. Dopfer-Jablonka, Alexandra Kaiser, Philipp D. Traenkle, Bjoern Rothbauer, Ulrich Krause, Gérard Schneiderhan-Marra, Nicole Behrens, Georg M.N. EBioMedicine Research Paper BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. FINDINGS: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. INTERPRETATION: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. FUNDING: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism. Elsevier 2021-08-12 /pmc/articles/PMC8357427/ /pubmed/34391096 http://dx.doi.org/10.1016/j.ebiom.2021.103524 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Strengert, Monika
Becker, Matthias
Ramos, Gema Morillas
Dulovic, Alex
Gruber, Jens
Juengling, Jennifer
Lürken, Karsten
Beigel, Andrea
Wrenger, Eike
Lonnemann, Gerhard
Cossmann, Anne
Stankov, Metodi V.
Dopfer-Jablonka, Alexandra
Kaiser, Philipp D.
Traenkle, Bjoern
Rothbauer, Ulrich
Krause, Gérard
Schneiderhan-Marra, Nicole
Behrens, Georg M.N.
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
title Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
title_full Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
title_fullStr Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
title_full_unstemmed Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
title_short Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
title_sort cellular and humoral immunogenicity of a sars-cov-2 mrna vaccine in patients on haemodialysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357427/
https://www.ncbi.nlm.nih.gov/pubmed/34391096
http://dx.doi.org/10.1016/j.ebiom.2021.103524
work_keys_str_mv AT strengertmonika cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT beckermatthias cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT ramosgemamorillas cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT dulovicalex cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT gruberjens cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT juenglingjennifer cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT lurkenkarsten cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT beigelandrea cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT wrengereike cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT lonnemanngerhard cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT cossmannanne cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT stankovmetodiv cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT dopferjablonkaalexandra cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT kaiserphilippd cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT traenklebjoern cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT rothbauerulrich cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT krausegerard cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT schneiderhanmarranicole cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis
AT behrensgeorgmn cellularandhumoralimmunogenicityofasarscov2mrnavaccineinpatientsonhaemodialysis